Advaxis licenses ISG15 tumor antigen from University of Pennsylvania

[News]

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has exclusively licensed the use of antigen ISG15 in Advaxis' Lm-LLO based immunotherapies from the University of Pennsylvania.

More... (http://www.news-medical.net/news/20111116/Advaxis-licenses-ISG15-tumor-antigen-from-University-of-Pennsylvania.aspx)